earnings
confidence high
sentiment positive
materiality 0.75
Anika Q2 revenue $38.1M (+24% YoY); raises FY revenue growth outlook to 11-14%
Anika Therapeutics, Inc.
2021-Q2 EPS reported
$0.64
revenue$72,437,000
- Net income $6.5M ($0.45 diluted EPS) vs net loss $7.7M in Q2 2020.
- Adjusted net income $1.4M ($0.09 diluted EPS); adjusted EBITDA $6.1M.
- Joint Preservation and Restoration revenue up 79% to $11.9M; segment now 31% of total.
- Company raises FY 2021 revenue growth guidance to 11-14% from prior 10-13%.
- First surgical case with WristMotion Total Wrist implant; 510(k) clearance for reverse shoulder system.